Mazankowski Alberta Heart Institute
Edmonton, Alberta, T6G 2B7, Canada
Location status: Recruiting
NCT Number: NCT05376254
This goal of this study is to analyze images of the right ventricle taken via 3D transesophageal echocardiography (TEE) during left ventricular assist device (LVAD) implantation.
Interested in participating?
Request Info16 year and older
All sexes
Observational
Edmonton, Alberta, T6G 2B7, Canada
Location status: Recruiting
There are two chambers in the heart known as ventricles which are responsible for pumping blood to both the lungs and the rest of the body. The right ventricle pumps blood to the lungs for oxygenation. The left ventricle then delivers this oxygenated blood to the organs in the body. When the left ventricle is damaged enough that it is not able to effectively pump blood then it may be necessary to assist it with a mechanical pump. This pump is called left ventricular assist device (LVAD).
Left ventricular assist devices (LVADs) improve quality of life and survival in patients with end stage heart failure. However, right ventricular (RV) failure is common in 20-50% of LVAD recipients and is associated with perioperative complications.
Traditional two-dimensional ultrasound views of the right ventricle may not accurately depict how well or poorly the right ventricle is working. Three-dimensional (3D) images can overcome the limitations of two-dimensional images and are becoming more commonplace. This goal of this study is to analyze images of the right ventricle taken via 3D transesophageal echocardiography (TEE) during the LVAD implantation to help predict which patients are at higher risk of right ventricular failure within 14 days of the procedure.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 hours
Prognostic indicator of hypertensive heart failure
Time frame: 24 hours
Percentage change in the RV chamber area between end-diastole to end-systole
Time frame: 24 hours
Prognostic indicator of pulmonary arterial hypertension
Time frame: 24 hours
Amount of blood in the heart's right ventricle just before the heart contracts
Time frame: 24 hours
Amount of blood in the heart's left ventricle just before the heart contracts
Time frame: 24 hours
Amount of blood in the heart's right ventricle just after the heart contracts
Time frame: 24 hours
Amount of blood in the heart's left ventricle just after the heart contracts
Time frame: 24 hours
Amount of blood being pumped out of the right ventricle each time it contracts.
Time frame: 24 hours
Amount of blood being pumped out of the left ventricle each time it contracts.
Time frame: 24 hours
Parameter of global right ventricular function
Time frame: 1 day
Demographic measure
Time frame: 1 day
Demographic measure
Time frame: 1 day
Demographic measure
Time frame: 14 days
Pressure in the thoracic vena cava near the right atrium
Time frame: 14 days
Hemodynamic index
Time frame: 14 days
Circulatory support
Time frame: 14 days
Supportive medication
Time frame: 14 days
Supportive medications
Time frame: 14 days
Lab test (> or qual to 80 IU/L)
Time frame: 14 days
Lab test (> 2.0 mg/dL)
Time frame: 14 days
Lab test (> or equal to 2.3 mg/dL)
Contact information is provided by the study sponsor or research team.
University of Alberta
Other
Three-Dimensional Assessment of Right Ventricular Function in Patients Undergoing Left Ventricular Assist Device Implantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07278583
Cardiovascular Diseases, Heart Diseases
Clermont-Ferrand, France
View Trial DetailsNCT07581587
Cardiovascular Diseases, Heart Diseases
Istanbul, Fatih, Turkey (Türkiye)
View Trial DetailsNCT07492524
Arrhythmias, Cardiac, Atrial Fibrillation
Yancheng, Dongtai, China
View Trial DetailsNCT07482943
Cardiovascular Abnormalities, Cardiovascular Diseases
Hong Kong
View Trial Details